Sek Kathiresan: Thrilled to Join Eli Lilly and Co. as Senior Vice President
OncoDaily GU · Pennsylvania
Visit company website
FULL-TIME
Posted Jun 24, 2026
Job Description
Career Updates
Oct 2, 2025 2:11 pm
Sek Kathiresan/X
Sek Kathiresan: Thrilled to Join Eli Lilly and Co. as Senior Vice President
Sek Kathiresan, Senior Vice President At Eli Lilly And Company, Chief Executive Officer, Founder At Verve Therapeutics, Shared a Post On X
“Delighted to share an update on the next chapter.
Today, thrilled to join Eli Lilly and Co. as Senior Vice President and help unite caring with discovery to create medicines that make life better for people around the world.
I will continue to lead Verve Therapeutics as CEO, where Verve Therapeutics operates as a wholly owned subsidiary of Lilly. Verve will continue operations in Boston and maintain its focus on gene editing medicines for cardiovascular disease.
We are all focused on one goal: develop our in vivo gene editing medicines, get them to market, and hopefully, transform the treatment of cardiovascular disease.”
More posts featuring Eli Lilly and Company on OncoDaily.
Stay Informed
Subscribe to OncoDaily Newsletter
Don't miss the latest news in oncology: stay up to date with daily picks from OncoDaily.
Subscribe
• Career Updates
cancer Eli Lilly and Company OncoDaily Oncology Sek Kathiresan Verve Therapeutics
Oct 2, 2025 2:11 pm
Sek Kathiresan/X
Sek Kathiresan: Thrilled to Join Eli Lilly and Co. as Senior Vice President
Sek Kathiresan, Senior Vice President At Eli Lilly And Company, Chief Executive Officer, Founder At Verve Therapeutics, Shared a Post On X
“Delighted to share an update on the next chapter.
Today, thrilled to join Eli Lilly and Co. as Senior Vice President and help unite caring with discovery to create medicines that make life better for people around the world.
I will continue to lead Verve Therapeutics as CEO, where Verve Therapeutics operates as a wholly owned subsidiary of Lilly. Verve will continue operations in Boston and maintain its focus on gene editing medicines for cardiovascular disease.
We are all focused on one goal: develop our in vivo gene editing medicines, get them to market, and hopefully, transform the treatment of cardiovascular disease.”
More posts featuring Eli Lilly and Company on OncoDaily.
Stay Informed
Subscribe to OncoDaily Newsletter
Don't miss the latest news in oncology: stay up to date with daily picks from OncoDaily.
Subscribe
• Career Updates
cancer Eli Lilly and Company OncoDaily Oncology Sek Kathiresan Verve Therapeutics
Additional Details
- State
- Pennsylvania
- Country
- US
Apply and matching require a free OVN account. Browse listings anytime without signing in.